CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法：在儿童血液系统恶性肿瘤中的现状与临床结局
英文原题：Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
查看英文原题
Chimeric Antigen Receptor T-cell Therapy: Current Status and Clinical Outcomes in Pediatric Hematologic Malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已经改变了复发/难治性B细胞急性淋巴细胞白血病（B-ALL）儿科患者的治疗模式，在关键的CD19-CART试验中，完全缓解率在65%至90%之间。伴随这种新疗法，新的毒性特征和治疗局限性已经出现，因此需要毒性共识分级系统、合作组试验和新的管理方法。本综述重点介绍了CAR-T 用于儿科血液恶性肿瘤的关键临床试验结果，讨论了迄今为止观察到的最常见毒性，并阐明了优化该疗法的挑战、机遇和活跃研究领域。
展开英文摘要原文
Chimeric antigen receptor T-cell (CART) therapy has transformed the treatment paradigm for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), with complete remission rates in key pivotal CD19-CART trials ranging from 65% to 90%.
Alongside this new therapy, new toxicity profiles and treatment limitations have emerged, necessitating toxicity consensus grading systems, cooperative group trials, and novel management approaches. This review highlights the results of key clinical trials of CART for pediatric hematologic malignancies, discusses the most common toxicities seen to date, and elucidates challenges, opportunities, and areas of active research to optimize this therapy.
论文信息
- 作者
- Talleur AC、Myers R、Annesley C、Shalabi H
- 第一作者单位
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS1130, Memphis, TN 38105, USA.United States
- 通讯作者单位
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1W-5750, 9000 Rockville Pike, Bethesda, MD 20892-1104, USA. Electronic address: haneen.shalabi@nih.gov.United States
- 文献类型
- 综述 · 非美国政府资助研究 · 美国 NIH 资助研究
- 期刊
- Hematology/oncology clinics of North America2022 Aug
- 原文标识
- PubMed 35780062 · DOI 10.1016/j.hoc.2022.03.005